hims & hers fda warning letter compounded semaglutide 2025 Hers' Super Bowl ad turns up the heat on GLP-1 battle From Crackdown to Collaboration: FDA

For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, verified vendor information, and a community of thousands who have navigated these exact sourcing questions

Weight loss drug coverage under Medicaid remains limited across most states, and Colorado is no exception

Sleep got better

This triple mechanism of action distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and is thought to produce more pronounced effects on weight reduction and metabolic control

Studies in humans have also confirmed that consuming fat and sugar simultaneously promotes overeating (Hedrih, 2024), likely due to increased reward responses from separate neural gut-brain pathways activated by sugar and fat (McDougle et al., 2024)